BACKGROUND: The aims of the present study were to ascertain the activation status of Akt in the primary cells of chronic lymphocytic leukemia and to investigate the effects of specific Akt inhibition on chronic lymphocytic leukemia-cell survival. DESIGN AND METHODS: Anti-phospho-Akt (Ser473 or Thr308) antibodies and western blotting were used to establish the activation status of Akt. The effects of two different, specific small-molecule inhibitors (A-443654 or Akti-1/2) or small interfering RNA on cell survival and downstream targets of Akt were assessed. Apoptosis was determined by fluorescence-activated cell sorting analysis of phosphatidylserine exposure and by measurement of PARP cleavage. The phosphorylation status of GSK-3 and MDM2, two immediate downstream substrates of Akt, levels of the anti-apoptotic proteins BCL2 and MCL1, and expression of p53 and p21 were all measured by western blotting. RESULTS: Fully activated Akt was demonstrable in all chronic lymphocytic leukemia clones examined (n=26). These results were validated with extensive controls and it was shown that a harsh method of cell extraction is needed for detection of the active enzyme. Specific inhibition of Akt induced extensive apoptosis of chronic lymphocytic leukemia cells, which was associated with both a rapid loss of MCL1 through proteasomal degradation and increased expression of p53. Moreover, the Akt inhibitors, at concentrations that induced extensive apoptosis in chronic lymphocytic leukemia cells, had little or no effect on normal peripheral blood mononuclear cells. CONCLUSIONS: Chronic lymphocytic leukemia clones consistently contain activated Akt which plays a pivotal role in maintaining cell survival. Inhibition of the Akt pathway may be of potential value as a novel therapeutic strategy in chronic lymphocytic leukemia.
BACKGROUND: The aims of the present study were to ascertain the activation status of Akt in the primary cells of chronic lymphocytic leukemia and to investigate the effects of specific Akt inhibition on chronic lymphocytic leukemia-cell survival. DESIGN AND METHODS: Anti-phospho-Akt (Ser473 or Thr308) antibodies and western blotting were used to establish the activation status of Akt. The effects of two different, specific small-molecule inhibitors (A-443654 or Akti-1/2) or small interfering RNA on cell survival and downstream targets of Akt were assessed. Apoptosis was determined by fluorescence-activated cell sorting analysis of phosphatidylserine exposure and by measurement of PARP cleavage. The phosphorylation status of GSK-3 and MDM2, two immediate downstream substrates of Akt, levels of the anti-apoptotic proteins BCL2 and MCL1, and expression of p53 and p21 were all measured by western blotting. RESULTS: Fully activated Akt was demonstrable in all chronic lymphocytic leukemia clones examined (n=26). These results were validated with extensive controls and it was shown that a harsh method of cell extraction is needed for detection of the active enzyme. Specific inhibition of Akt induced extensive apoptosis of chronic lymphocytic leukemia cells, which was associated with both a rapid loss of MCL1 through proteasomal degradation and increased expression of p53. Moreover, the Akt inhibitors, at concentrations that induced extensive apoptosis in chronic lymphocytic leukemia cells, had little or no effect on normal peripheral blood mononuclear cells. CONCLUSIONS:Chronic lymphocytic leukemia clones consistently contain activated Akt which plays a pivotal role in maintaining cell survival. Inhibition of the Akt pathway may be of potential value as a novel therapeutic strategy in chronic lymphocytic leukemia.
Authors: John R Mills; Yoshitaka Hippo; Francis Robert; Samuel M H Chen; Abba Malina; Chen-Ju Lin; Ulrike Trojahn; Hans-Guido Wendel; Al Charest; Roderick T Bronson; Scott C Kogan; Robert Nadon; David E Housman; Scott W Lowe; Jerry Pelletier Journal: Proc Natl Acad Sci U S A Date: 2008-07-29 Impact factor: 11.205
Authors: Nelson Rhodes; Dirk A Heerding; Derek R Duckett; Derek J Eberwein; Victoria B Knick; Timothy J Lansing; Randy T McConnell; Tona M Gilmer; Shu-Yun Zhang; Kimberly Robell; Jason A Kahana; Robert S Geske; Elena V Kleymenova; Anthony E Choudhry; Zhihong Lai; Jack D Leber; Elisabeth A Minthorn; Susan L Strum; Edgar R Wood; Pearl S Huang; Robert A Copeland; Rakesh Kumar Journal: Cancer Res Date: 2008-04-01 Impact factor: 12.701
Authors: Feng-Ting Liu; Samir G Agrawal; John G Gribben; Hongtao Ye; Ming-Qing Du; Adrian C Newland; Li Jia Journal: Blood Date: 2007-12-26 Impact factor: 22.113
Authors: V Papa; P L Tazzari; F Chiarini; A Cappellini; F Ricci; A M Billi; C Evangelisti; E Ottaviani; G Martinelli; N Testoni; J A McCubrey; A M Martelli Journal: Leukemia Date: 2007-10-11 Impact factor: 11.528
Authors: Jeremy T Larsen; Tait D Shanafelt; Jose F Leis; Betsy LaPlant; Tim Call; Adam Pettinger; Curtis Hanson; Charles Erlichman; Thomas Matthew Habermann; Craig Reeder; Daniel Nikcevich; Deborah Bowen; Michael Conte; Justin Boysen; Charla Secreto; Connie Lesnick; Renee Tschumper; Diane Jelinek; Neil E Kay; Wei Ding Journal: Am J Hematol Date: 2017-06-01 Impact factor: 10.047
Authors: Lynda B Bennett; Kristen H Taylor; Gerald L Arthur; Farahnaz B Rahmatpanah; Sam I Hooshmand; Charles W Caldwell Journal: Epigenomics Date: 2010-02-01 Impact factor: 4.778
Authors: Kamira Maharaj; John J Powers; Alex Achille; Susan Deng; Renee Fonseca; Mibel Pabon-Saldana; Steven N Quayle; Simon S Jones; Alejandro Villagra; Eduardo M Sotomayor; Eva Sahakian; Javier Pinilla-Ibarz Journal: Blood Adv Date: 2018-11-13
Authors: Emilio Cosimo; Anuradha Tarafdar; Michael W Moles; Ailsa K Holroyd; Natasha Malik; Mark A Catherwood; Jodie Hay; Karen M Dunn; Alan M Macdonald; Sylvie M Guichard; Declan O'Rourke; Michael T Leach; Owen J Sansom; Sabina C Cosulich; Alison M McCaig; Alison M Michie Journal: Clin Cancer Res Date: 2018-12-17 Impact factor: 12.531